Amycretin Research for Obesity
An evidence-based overview of research examining Amycretin in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Amycretin Phase 1 trials demonstrated substantial weight loss in adults with obesity. Oral formulation showed ~13% weight loss at 12 weeks, while subcutaneous formulation achieved up to ~22% at 36 weeks. These signals exceed single-mechanism GLP-1 agonists at comparable timepoints, validating the dual-agonist approach.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Amycretin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.